A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment

Suzuki,Shinya; Nawata,Shuichi; Inada,Yusuke; Sato,Daisuke; Kusano,Junichi; Ichikura,Daisuke; Torigoe,Kazuhiro; Ishitsuka,Kazumi; Sato,Fumiaki; Sakai,Hiroyasu; Yumoto,Tetsuro

doi:10.3892/mco.2018.1689

October-2018 Volume 9 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October-2018 Volume 9 Issue 4

Full Size Image

Article

A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment

Authors:
- Shinya Suzuki
- Shuichi Nawata
- Yusuke Inada
- Daisuke Sato
- Junichi Kusano
- Daisuke Ichikura
- Kazuhiro Torigoe
- Kazumi Ishitsuka
- Fumiaki Sato
- Hiroyasu Sakai
- Tetsuro Yumoto
View Affiliations / Copyright

Affiliations: Department of Pharmacy, Kanagawa Prefectural Keiyukai Keiyu Hospital, Yokohama, Kanagawa 220‑8521, Japan, Department of Hospital Pharmaceutics, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa 224‑8503, Japan, Department of Pharmaceutical Services, Yokohama Rosai Hospital, Yokohama, Kanagawa 222-0036, Japan, Department of Pharmacy, Fujisawa City Hospital, Fujisawa, Kanagawa 251-8550, Japan, Division of Applied Pharmaceutical Education and Research, Hoshi University, Tokyo 142-8501, Japan, Department of Analytical Pathophysiology, Hoshi University, Tokyo 142-8501, Japan
Pages: 443-448
|
Published online on: August 2, 2018

https://doi.org/10.3892/mco.2018.1689
Expand metrics +

Abstract

Medical personnel actively provide patients taking capecitabine with information on the items to prevent and treat hand-foot syndrome (HFS). However, they are typically unable to ascertain the extent of patient compliance with the recommended items. Thus, the aim of the present study was to ascertain the association between patient compliance with preventative measures for HFS and the development of HFS. Subjects included 90 patients who were treated with a drug regimen that included capecitabine. Patients were treated at one of four facilities between July 2015 and January 2017. The main parameters studied were the extent to which items to prevent and treat HFS were (or were not) followed, and the associaiton between this extent and the development of HFS symptoms. A manual prepared by a pharmaceutical company that manufactures capecitabine describes 15 routine items to follow in order to prevent and treat HFS. The two activities patients most often performed were ‘applying a moisturizer’ (74.1%) and ‘keeping one's skin clean (e.g., washing one's hands and feet)’ (64.7%). The two activities patients least often performed were ‘using sunscreen on exposed areas’ (14.1%) and ‘using soft insoles’ (11.8%). Patients who performed more items to prevent and treat HFS were significantly less likely to develop symptoms of HFS (P=0.022). Based on these findings, it is recommended that medical personnel provide instructions to the patients regarding the specific items necessary to prevent and treat HFS, and to follow-up with the patients regarding their compliance, with an emphasis on the items they are less likely to take and on the instructions to avoid external irritants. Following these guidelines should lead to qualitative improvement in HFS management.

View Figures

View References

1	Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 352:2696–2704. 2005. View Article : Google Scholar : PubMed/NCBI
2	Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
3	Tsuboi H, Yonemoto K and Katsuoka K: A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol. 32:921–925. 2005. View Article : Google Scholar : PubMed/NCBI
4	Nikolaou V, Syrigos K and Saif MW: Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 15:1625–1633. 2016. View Article : Google Scholar : PubMed/NCBI
5	Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC and Hutchins KS: Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract. 9:161–166. 2003. View Article : Google Scholar
6	Lassere Y and Hoff P: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs. 8:S31–S40. 2004. View Article : Google Scholar : PubMed/NCBI
7	Gressett SM, Stanford BL and Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 12:131–141. 2006. View Article : Google Scholar : PubMed/NCBI
8	Nagore E, Insa A and Sanmartín O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 1:225–234. 2000. View Article : Google Scholar : PubMed/NCBI
9	Nakane M: Neurotoxicity and Dermatologic Toxicity of Cancer Chemotherapy. Jpn J Cancer Chemother. 33:29–33. 2006.
10	Mae Y, Yokokawa T, Kawakami K, Yagi N, Suenaga M, Shinozaki E, Matsusaka S, Mizunuma N and Hama T: Usefulness of Pharmaceutical Outpatient Clinic in XELOX Therapy. Jpn J Pharm Health Care Sci. 37:611–615. 2011. View Article : Google Scholar
11	Morimoto E and Inoue N: Current state of nursing care for prevention of hand-foot-syndrome from capecitabine, from the study for certified nurse in cancer chemotherapy nursing in Japan. J Jpn Soc Cancer Nurs. 28:30–36. 2014.
12	Chugai Pharmaceutical Co. Ltd; Hand-Foot Syndrome Atlas. 3rd edition. Tokyo: 2011
13	Yamazaki N and Taguchi T: Hand-foot syndrome. J Clin Exp Med. 216:257–260. 2006.
14	Yokokawa T, Kawakami K, Mae Y, Sugita K, Watanabe H, Suzuki K, Suenaga M, Mizunuma N, Yamaguchi T and Hama T: Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother. 49:1120–1124. 2015. View Article : Google Scholar : PubMed/NCBI
15	Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, et al: Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 14:1735–1743. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

A cross-sectional survey of methods for controling hand-foot syndrome in patients receiving capecitabine treatment

This article is mentioned in:

Abstract

Figure 1

Related Articles